HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Grundy, S. M. Search for Related Content PubMed PubMed Citation Articles by Grundy, S. M. Related Collections Lipids, Lipoproteins, and Cardiovascular Risk Factors Endocrinology and Metabolism

Point: The Metabolic Syndrome Still Lives

Center for Human Nutrition and Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Y3.206, Dallas, TX 75390-9052. Fax 214-648-4837; e-mail scott.grundy@utsouthwestern.edu.

The first 300 words of the full text of this article appear below.

	Introduction

 
Dr. Gerald Reaven’s report (1) of the death of the metabolic syndrome may be exaggerated. Whether his obituary relates specifically to the National Cholesterol Education Program’s Adult Treatment Panel III (ATP III) (2) definition of metabolic syndrome or to all attempts at making a clinical definition of the metabolic syndrome is unclear. Regardless, he does a thorough autopsy on the ATP III report and appears to find widespread systemic disease. After reading his postmortem examination, however, one wonders whether he is reporting on the death of the syndrome or rather is dissecting it while it is still alive. The editors of Clinical Chemistry have given me a last chance to resuscitate what appears to be a badly mangled body. In my examination of the corpus, however, I see signs of life. Thanks to advances of modern medicine, it may be possible achieve survival. This is my assigned task.

Of interest is the fact that Dr. Reaven’s sharp blade cuts only into the ATP III definition of the metabolic syndrome. Other definitions escape his knife, specifically those of the WHO (3), the European Group on Insulin Resistance (EGIR) (4), and the American Association of Clinical Endocrinologists (AACE) (5). The definitions put forward by these organizations are similar to those of ATP III, but apparently Dr. Reaven believes that the ATP III is the most flawed of the group. Because I was a member of the team that issued the ATP III criteria, perhaps I can offer a rationale for having done so. Several points can be made in their defense.

	Clinical Management of Obesity and Its Metabolic Complications

 
In 1993, the ATP II report (6) placed increased emphasis on management of obesity to reduce risk for atherosclerotic cardiovascular disease (ASCVD). This emphasis was not widely adopted by . . . [Full Text of this Article]

	Renewed Emphasis on Long-Term (Lifetime) Risk

 

	Stimulation of Epidemiologic Research

 

	Stimulation of Basic and Clinical Research

 

The following articles in journals at HighWire Press have cited this article:

				H. Bergman, L. Ferrucci, J. Guralnik, D. B. Hogan, S. Hummel, S. Karunananthan, and C. Wolfson Frailty: An Emerging Research and Clinical Paradigm Issues and Controversies J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2007; 62(7): 731 - 737. [Abstract] [Full Text] [PDF]

				E. Goodman, S. R. Daniels, J. B. Meigs, and L. M. Dolan Instability in the Diagnosis of Metabolic Syndrome in Adolescents Circulation, May 1, 2007; 115(17): 2316 - 2322. [Abstract] [Full Text] [PDF]

				S. J. L. Bakker, R. T. Gansevoort, and D. de Zeeuw Metabolic syndrome: a fata morgana? Nephrol. Dial. Transplant., January 1, 2007; 22(1): 15 - 20. [Full Text] [PDF]

				D. M. Capuzzi and J. S. Freeman C-Reactive Protein and Cardiovascular Risk in the Metabolic Syndrome and Type 2 Diabetes: Controversy and Challenge Clin. Diabetes, January 1, 2007; 25(1): 16 - 22. [Abstract] [Full Text] [PDF]

				J. L. Gonzalez-Sanchez, M. T. Martinez-Larrad, M. E. Saez, C. Zabena, M. J. Martinez-Calatrava, and M. Serrano-Rios Endothelial Nitric Oxide Synthase Haplotypes Are Associated with Features of Metabolic Syndrome Clin. Chem., January 1, 2007; 53(1): 91 - 97. [Abstract] [Full Text] [PDF]

				M. Blaha and T. A. Elasy Clinical Use of the Metabolic Syndrome: Why the Confusion? Clin. Diabetes, July 1, 2006; 24(3): 125 - 131. [Abstract] [Full Text] [PDF]

				C. Lorenzo, M. Serrano-Rios, M. T. Martinez-Larrad, J. L. Gonzalez-Sanchez, S. Seclen, A. Villena, C. Gonzalez-Villalpando, K. Williams, and S. M. Haffner Geographic Variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III Definitions of the Metabolic Syndrome in Nondiabetic Subjects. Diabetes Care, March 1, 2006; 29(3): 685 - 691. [Abstract] [Full Text] [PDF]

				G. Reaven Counterpoint: Just Being Alive Is Not Good Enough Clin. Chem., August 1, 2005; 51(8): 1354 - 1357. [Full Text] [PDF]